Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS)
commonly affect older men. Age-related changes associated with metabolic disturbances …

CONTEXT: Several randomized controlled trials (RCTs) on phosphodiesterase type 5
inhibitors (PDE5-Is) have showed significant improvements in both lower urinary tract …

Metabolic syndrome (MetS) is a complex entity consisting of multiple interrelated factors
including insulin resistance, central adiposity, dyslipidemia, endothelial dysfunction and …

Importance Combining 2 first-line treatments for erectile dysfunction (ED) or initiating other
modalities in addition to a first-line therapy may produce beneficial outcomes. Objective To …

Accepted for publication January 23, 2012. cerebrovascular disease, diabetes,
hypertension, obstructive sleep apnea, and normal-pressure hydrocephalus. Functional …

Background Several drugs are approved for the treatment of lower urinary tract symptoms
(LUTS) in men, but these are mostly used by clinicians as monotherapies. The combination …

Abstract Context Alpha-blockers (ABs) and 5-alpha reductase inhibitors have an established
role in treating male lower urinary tract symptoms (LUTS) attributed to benign prostatic …

The metabolic syndrome is common in countries with Western lifestyles. It comprises a
number of disorders—including insulin resistance, hypertension and obesity—that all act as …

Introduction Lower urinary tract symptoms (LUTS) associated with benign prostatic
hyperplasia (BPH) and erectile dysfunction are common disorders of advancing age. Aim To …

Background Benign prostatic hyperplasia (BPH) refers to non‐malignant enlargement of the
prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha …